Likert与PI-RADS v2在前列腺癌检测中的比较
该研究对489例连续患者的前列腺多参数MRI进行前瞻性配对报告,比较Likert与PI-RADS v2对临床显著前列腺癌的检测价值。结果显示两种评分系统活检决策率相似,但Likert在所有临床显著癌定义下均预测更多显著癌,且ROC曲线下总面积和部分面积更高,诊断性能优于PI-RADS v2。
要点
- Likert与PI-RADS v2活检决策率相似(83.8% vs 84.8%,P=0.704)。
- Likert在所有临床显著癌阈值下均预测更多显著癌。
- Likert的ROC曲线下总面积和部分面积均高于PI-RADS v2。
核心结论
- 两种评分系统诊断性能均良好且活检决策率相似,但Likert在所有临床显著前列腺癌定义下均优于PI-RADS v2。
研究设计与样本
- 对489例连续患者的活检前多参数MRI扫描,由专家泌尿放射科医生前瞻性配对使用Likert和PI-RADS v2报告。
主要发现
- 中位年龄66岁(IQR 60-72),中位PSA 7 ng/mL(IQR 5-10)。
- 达到活检阈值并接受活检的比例相似:Likert 83.8% vs PI-RADS v2 84.8%(P=0.704)。
- Likert在所有疾病阈值下预测更多临床显著癌,两组非显著癌检出率相当。
- 在活检患者中,Likert的ROC曲线下总面积和部分面积均高于PI-RADS v2。
关键数值与推荐
- 主要显著癌阈值:Gleason ≥3+4。
- 次要阈值:Gleason ≥4+3、Ahmed/UCL1(Gleason ≥4+3或最大癌核心长度≥6或总癌核心长度≥6)、Ahmed/UCL2(Gleason ≥3+4或最大癌核心长度≥4或总癌核心长度≥6)。
临床怎么用
- Likert评分灵活、直观且可纳入临床数据,但应在放射科医生积累足够前列腺mpMRI报告经验后使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the clinical validity and utility of Likert assessment and the Prostate Imaging Reporting and Data System (PI-RADS) v2 in the detection of clinically significant and insignificant prostate cancer. PATIENTS AND METHODS: A total of 489 pre-biopsy multiparametric magnetic resonance imaging (mpMRI) scans in consecutive patients were subject to prospective paired reporting using both Likert and PI-RADS v2 by expert uro-radiologists. Patients were offered biopsy for any Likert or PI-RADS score ≥4 or a score of 3 with PSA density ≥0.12 ng/mL/mL. Utility was evaluated in terms of proportion biopsied, and proportion of clinically significant and insignificant cancer detected (both overall and on a 'per score' basis). In those patients biopsied, the overall accuracy of each system was assessed by calculating total and partial area under the receiver-operating characteristic (ROC) curves. The primary threshold of significance was Gleason ≥3 + 4. Secondary thresholds of Gleason ≥4 + 3, Ahmed/UCL1 (Gleason ≥4 + 3 or maximum cancer core length [CCL] ≥6 or total CCL≥6) and Ahmed/UCL2 (Gleason ≥3 + 4 or maximum CCL ≥4 or total CCL ≥6) were also used. RESULTS: The median (interquartile range [IQR]) age was 66 (60-72) years and the median (IQR) prostate-specific antigen level was 7 (5-10) ng/mL. A similar proportion of men met the biopsy threshold and underwent biopsy in both groups (83.8% [Likert] vs 84.8% [PI-RADS v2]; P = 0.704). The Likert system predicted more clinically significant cancers than PI-RADS across all disease thresholds. Rates of insignificant cancers were comparable in each group. ROC analysis of biopsied patients showed that, although both scoring systems performed well as predictors of significant cancer, Likert scoring was superior to PI-RADS v2, exhibiting higher total and partial areas under the ROC curve. CONCLUSIONS: Both scoring systems demonstrated good diagnostic performance, with similar rates of decision to biopsy. Overall, Likert was superior by all definitions of clinically significant prostate cancer. It has the advantages of being flexible, intuitive and allowing inclusion of clinical data. However, its use should only be considered once radiologists have developed sufficient experience in reporting prostate mpMRI.
引用
- Khoo CC, Eldred-Evans D, Peters M, et al. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer. BJU Int. 2019. PMID: 31599113. doi:10.1111/bju.14916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。